Characterization of the type-specific and cross-reactive B cell responses elicited by a live-attenuated tetravalent dengue vaccine.

BACKGROUND Dengue is caused by four antigenically distinct serotypes of dengue virus (DENV1-4). Takeda's live attenuated tetravalent dengue vaccine (TAK-003) candidate is composed of an attenuated DENV2 and chimeric viruses containing prM/E of DENV1, 3 and 4 on the DENV2 backbone. The Multi-Color FluoroSpot (MCF) assay enables quantitation of serotype-specific and cross-reactive individual memory B cells (MBCs) secreting DENV-specific antibodies in a polyclonal mixture. METHODS Using the MCF assay, we determined the type-specific and cross-reactive MBC response in peripheral blood mononuclear cells collected pre- and post-vaccination from 7 macaques and 15 randomly selected individuals who received TAK-003 (8 DENV-seronegative and 7 DENV-seropositive) in a Phase 2 clinical trial in Singapore (DEN-205 study). RESULTS Pre-existing DENV-specific MBC responses were detected only in seropositive vaccine recipients at day 0. Following vaccination, both type-specific and cross-reactive MBCs to all four DENV serotypes were observed in all macaques and clinical trial participants. The proportion of type-specific MBCs was higher than cross-reactive MBCs and remained stable between day 30 and 360 post-vaccination. CONCLUSIONS These results demonstrate that, unlike primary or secondary natural DENV infection, tetravalent vaccination elicits tetravalent type-specific MBCs, and thus all four components of TAK-003 contribute to the DENV-specific MBC response following vaccination.

• Publication year

  2020

• Venue

  Journal of Infectious Diseases

• Publication date

  2020-06-23

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1093/infdis/jiaa346PMID 32572472
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Primary and secondary dengue virus infections elicit similar memory B cell responses but breadth to other serotypes and cross-reactivity to Zika virus is higher in secondary dengue.

  2020cited by this paper
• Mapping global variation in dengue transmission intensity

  2020cited by this paper
• Safety and immunogenicity of a single dose of a tetravalent dengue vaccine with two different serotype-2 potencies in adults in Singapore: A phase 2, double-blind, randomised, controlled trial.

  2019cited by this paper
• Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and Adolescents.

  2019cited by this paper
• Impact of pre-existing dengue immunity on human antibody and memory B cell responses to Zika

  2019cited by this paper
• Activation Dynamics and Immunoglobulin Evolution of Pre-existing and Newly Generated Human Memory B cell Responses to Influenza Hemagglutinin.

  2019cited by this paper
• Is Dengvaxia a useful vaccine for dengue endemic areas?

  2019cited by this paper
• Longitudinal Analysis of Memory B and T Cell Responses to Dengue Virus in a 5-Year Prospective Cohort Study in Thailand

  2019cited by this paper
• ELISPOT-Based "Multi-Color FluoroSpot" to Study Type-Specific and Cross-Reactive Responses in Memory B Cells after Dengue and Zika Virus Infections.

  2018cited by this paper
• Dissecting Antibodies Induced by a Chimeric Yellow Fever–Dengue, Live-Attenuated, Tetravalent Dengue Vaccine (CYD-TDV) in Naive and Dengue-Exposed Individuals

  2016cited by this paper
• Safety and Immunogenicity of a Tetravalent Dengue Vaccine Candidate in Healthy Children and Adults in Dengue-Endemic Regions: A Randomized, Placebo-Controlled Phase 2 Study.

  2016cited by this paper
• Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease.

  2015cited by this paper
• Safety and Immunogenicity of a Live Attenuated Tetravalent Dengue Vaccine Candidate in Flavivirus-Naive Adults: A Randomized, Double-Blinded Phase 1 Clinical Trial.

  2015cited by this paper
• Dengue viruses cluster antigenically but not as discrete serotypes

  2015cited by this paper
• Safety and immunogenicity of different doses and schedules of a live attenuated tetravalent dengue vaccine (TDV) in healthy adults: A Phase 1b randomized study.

  2015cited by this paper
• Development of a recombinant, chimeric tetravalent dengue vaccine candidate.

  2015cited by this paper
• Single-Cell Analysis of B Cell/Antibody Cross-Reactivity Using a Novel Multicolor FluoroSpot Assay

  2015cited by this paper
• Dengue

  2015cited by this paper
• Virus-specific antibody secreting cell, memory B-cell, and sero-antibody responses in the human influenza challenge model.

  2014cited by this paper
• Isolation of Dengue Virus-Specific Memory B Cells with Live Virus Antigen from Human Subjects following Natural Infection Reveals the Presence of Diverse Novel Functional Groups of Antibody Clones

  2014cited by this paper
• Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study.

  2014cited by this paper
• Homology and conservation of amino acids in E-protein sequences of dengue serotypes

  2014cited by this paper
• Dengue Viruses Are Enhanced by Distinct Populations of Serotype Cross-Reactive Antibodies in Human Immune Sera

  2014cited by this paper
• High-Avidity and Potently Neutralizing Cross-Reactive Human Monoclonal Antibodies Derived from Secondary Dengue Virus Infection

  2013cited by this paper
• Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions

  2012cited by this paper
• The Human Antibody Response to Dengue Virus Infection

  2011cited by this paper
• B-cell responses during primary and secondary dengue virus infections in humans.

  2011cited by this paper
• Memory B cells, but not long-lived plasma cells, possess antigen specificities for viral escape mutants

  2011cited by this paper
• The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity.

  2010cited by this paper
• Antibodies and B cell memory in viral immunity.

  2007cited by this paper
• Analysis of repeat hospital admissions for dengue to estimate the frequency of third or fourth dengue infections resulting in admissions and dengue hemorrhagic fever, and serotype sequences.

  2007cited by this paper
• Research on dengue during World War II.

  1952cited by this paper

• The TAK-003 story: key decisions that shaped development of a tetravalent dengue vaccine

  2026cites this paper
• Dengue virus infection reprograms baseline innate immune gene expression.

  2025cites this paper
• TAK-003: development of a tetravalent dengue vaccine

  2025cites this paper
• Recent Advancements in Mosquito-Borne Flavivirus Vaccine Development

  2023cites this paper
• Vaccine development for mosquito-borne viral diseases

  2023cites this paper
• Bridging the immunogenicity of a tetravalent dengue vaccine (TAK-003) from children and adolescents to adults

  2023cites this paper
• Reply to de Silva and White

  2022influential citation
• Specificity and Breadth of the Neutralizing Antibody Response to a Live-Attenuated Tetravalent Dengue Vaccine

  2022cites this paper
• Controlled Human Infection Models To Accelerate Vaccine Development

  2022cites this paper
• Cross-reactive inhibitory antibody and memory B cell responses to variant strains of Duffy binding protein II at post-Plasmodium vivax infection

  2022cites this paper
• Antibodies Produced in Response to a Live-Attenuated Dengue Vaccine Are Functional in Activating the Complement System

  2022cites this paper
• Neutralization Fingerprinting Technology for Characterizing Polyclonal Antibody Responses to Dengue Vaccines

  2021cites this paper
• Development and Characterization of a Multiplex Assay to Quantify Complement-Fixing Antibodies against Dengue Virus

  2021cites this paper
• Dengue vaccine development by the year 2020: challenges and prospects

  2020cites this paper